Related references
Note: Only part of the references are listed.The evolving role of immune cells in prostate cancer
Chao Wang et al.
CANCER LETTERS (2022)
The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial
Alan Pollack et al.
LANCET (2022)
Epigenome-wide DNA methylation and transcriptome profiling of localized and locally advanced prostate cancer: Uncovering new molecular markers
Qian Liu et al.
GENOMICS (2022)
The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors
Sujun Chen et al.
NATURE COMMUNICATIONS (2022)
Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial
Vedang Murthy et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Snail/PRMT5/NuRD complex contributes to DNA hypermethylation in cervical cancer by TET1 inhibition
Jie Gao et al.
CELL DEATH AND DIFFERENTIATION (2021)
Genome-wide plasma DNA methylation features of metastatic prostate cancer
Anjui Wu et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
The DNA methylation landscape of advanced prostate cancer
Shuang G. Zhao et al.
NATURE GENETICS (2020)
Epigenetic regulation of prostate cancer
Ruixin Wang et al.
GENES & DISEASES (2020)
The Landscape of Immune Cells Infiltrating in Prostate Cancer
Zhicong Wu et al.
FRONTIERS IN ONCOLOGY (2020)
Identification of key DNA methylation-driven genes in prostate adenocarcinoma: an integrative analysis of TCGA methylation data
Ning Xu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
The comprehensive role of E-cadherin in maintaining prostatic epithelial integrity during oncogenic transformation and tumor progression
Adam Olson et al.
PLOS GENETICS (2019)
Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial
Piet Ost et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
DNA methyltransferase 3A isoform b contributes to repressing Ecadherin through cooperation of DNA methylation and H3K27/H3K9 methylation in EMT-related metastasis of gastric cancer
He Cui et al.
ONCOGENE (2018)
Regulation of prostate cancer by hormone-responsive G protein-coupled receptors
Wei Wang et al.
PHARMACOLOGY & THERAPEUTICS (2018)
DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer
Varun Sasidharan Nair et al.
CLINICAL EPIGENETICS (2018)
Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial
Mack Roach et al.
LANCET ONCOLOGY (2018)
The importance of DNA methylation in prostate cancer development
Charles E. Massie et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2017)
Telomeres and telomerase in prostate cancer development and therapy
Mindy Kim Graham et al.
NATURE REVIEWS UROLOGY (2017)
Ubiquitin C-terminal hydrolase isozyme L1 is associated with shelterin complex at interstitial telomeric sites
Aleksandar Ilic et al.
EPIGENETICS & CHROMATIN (2017)
A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)
Noura Radwan et al.
BMC CANCER (2017)
Global analysis of H3K27me3 as an epigenetic marker in prostate cancer progression
Marjolaine Ngollo et al.
BMC CANCER (2017)
Is There a Role for Pelvic Irradiation in Localized Prostate Adenocarcinoma? Update of the Long-Term Survival Results of the GETUG-01 Randomized Study
Pascal Pommier et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Alterations of Global Histone H3K9 and H3K27 Methylation Levels in Bladder Cancer
Joerg Ellinger et al.
UROLOGIA INTERNATIONALIS (2014)
DNA Methylation Changes Correlate with Gleason Score and Tumor Stage in Prostate Cancer
Lissette Delgado-Cruzata et al.
DNA AND CELL BIOLOGY (2012)
PELVIC NODAL RADIOTHERAPY IN PATIENTS WITH UNFAVORABLE INTERMEDIATE AND HIGH-RISK PROSTATE CANCER: EVIDENCE, RATIONALE, AND FUTURE DIRECTIONS
Lisa K. Morikawa et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Duration of Androgen Suppression in the Treatment of Prostate Cancer
Michel Bolla et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01
Pascal Pommier et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions
Colleen A. Lawton et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Whole-pelvis, mini-pelvis, or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial
Mack Roach et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation therapy oncology group 9413
M Roach et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: High incidence of lymph node metastasis
A Heidenreich et al.
JOURNAL OF UROLOGY (2002)
Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on radiation therapy oncology group clinical trials
M Roach et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2000)
Share Paper
